Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Invesco Dynamic Biotechnology & Genome ETF PBE
$61.49
-$0.58 (-0.94%)
На 18:01, 12 мая 2023
Ключевые показатели
-
Marketcap
282373000.00000000
-
week52high
68.50
-
week52low
51.39
-
Revenue
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
3.77293730
-
Last Dividend
1.37200000
-
Next Earnings Date
07 мая 2023 г. в 01:45
Описание компании
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Zacks Investment Research
03 мая 2023 г. в 07:39
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Dynamic Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Zacks Investment Research
07 апр 2023 г. в 07:40
Smart Beta ETF report for PBE
PBE: Healthcare Dashboard For March
Seeking Alpha
16 мар 2023 г. в 06:31
The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Zacks Investment Research
27 февр 2023 г. в 07:32
Sector ETF report for PBE
5 Least-Hurt Biotech ETFs of the Last Week
Zacks Investment Research
15 февр 2023 г. в 14:18
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.